Vancouver, British Columbia — August 7, 2025 — Leads & Copy — Zymeworks Inc. (Nasdaq: ZYME) announced that the FDA has cleared the investigational new drug (IND) application for ZW251, with first-in-human studies planned to initiate in 2025. The company also reported $48.7 million in revenue for Q2 2025, driven by progress on existing partnerships. Additionally, China and European approval for zanidatamab in 2L HER2-positive biliary tract cancer (BTC) expands international patient access.
Zymeworks’ CEO, Kenneth Galbraith, highlighted the strength and versatility of the Azymetric platform and the strategic partnership model. The company’s cash resources totaled $333.4 million as of June 30, 2025, providing a projected cash runway into 2H-2027.
Recent developments include preclinical data for ZW1528, a novel IL-4Rα x IL-33 bispecific molecule, and trial in progress posters for ZW171 and ZW191 presented at ASCO and ESMO conferences.
Zanidatamab continues to progress with long-term data from a Phase 2 trial announced by partner Jazz, and conditional approval in China for HER2+ BTC announced by partner BeOne Medicines. The European Commission also granted conditional marketing authorization of Ziihera® for HER2+ BTC.
Platform collaboration agreements include revenue recognition from BMS and Phase 1 trial results for pasritamig (JNJ-78278343) reported by J&J.
Zymeworks reported net income of $2.3 million in 2Q-2025, compared to a net loss of $37.7 million in 2Q-2024.
Contacts:
Investor Inquiries:
Shrinal Inamdar
Senior Director, Investor Relations
(604) 678-1388
ir@zymeworks.com
Media Inquiries:
Diana Papove
Senior Director, Corporate Communications
(604) 678-1388
media@zymeworks.com
Source: Zymeworks Inc.
